Leiomyosarcoma Clinical Trial
Official title:
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
Verified date | March 2014 |
Source | AGO Study Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Uterine sarcomas account for less than 5% of all carcinomas of the uterine corpus. The
prognosis of these patients is extremely limited. Recurrence rates of 50-60% are reported
even for early-stage disease (FIGO I/II). Median overall survival is below 12 months in
patients with advanced or metastatic disease.
Ovarian carcinosarcoma is extremely rare among ovarian malignancies (< 2%). That is why
there is insufficient data as a basis for establishing a gold standard. As a result, these
cases tend to be treated in the same way as uterine sarcomas or epithelial ovarian
malignancies in clinical practice.
On the basis of data published to date on the treatment of mixed mesenchymal-epithelial
tumors, it is clear that the treatments commonly used to date have limited activity while
producing clinically relevant toxicity. The regimes verified so far (Cisplatin / Ifosfamide,
Ifosfamide/Paclitaxel and Gemcitabine/Docetaxel) exhibit a considerable side effect spectrum
and are only rarely feasible on clinical everyday life conditions, so e. g. the rate of
withdrawals due to toxicity was in a study collective of selected females treated with the
last combination at 40 %. The physician has to check in every individual case if one of the
above mentioned combinations is feasible. The search for alternative effective and better
tolerated treatment options is essential. The toxicity data on the carboplatin-PLD
combination are known, and efficacy has been identified in small cohorts.
The objective of this study is to explore the efficacy of combination PLD-carboplatin
treatment in a larger patient population.
Status | Completed |
Enrollment | 41 |
Est. completion date | January 2012 |
Est. primary completion date | November 2011 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically documented mesenchymal or mixed epithelial-mesenchymal tumor of the ovary or uterus - Patients with a primary diagnosis of FIGO I-IV uterine carcinosarcoma and optimum debulking (postoperative residual tumor < 1cm) may be enrolled only if cisplatin-ifosfamide combination therapy is not feasible. - Patients with metastatic uterine carcinosarcoma may be enrolled only if Ifosfamide/Paclitaxel combination therapy is not feasible. - Patients with metastatic leiomyosarcoma may be enrolled only if gemcitabine-docetaxel combination therapy is not feasible. - Measurable (target lesion) tumor, evaluable (non-target lesion) tumor or histological documentation - No more than one prior chemotherapy. Any prior platinum or anthracycline- containing chemotherapy must have been completed more than 6 months previously - Prior radiotherapy = 25% of the hematopoietic system is allowed provided it took place more than 6 weeks before recruitment - Patients are allowed to have received prior anticancer hormone therapy or specific immunotherapy. Patients must have completed these therapies at least three weeks before recruitment to the study - All women with a theoretical possibility of pregnancy must produce a negative pregnancy test (serum or urinary) within seven days before starting treatment - General health of 0 - 2 on the ECOG score - At least 18 years of age - Estimated life expectancy above 12 weeks - At least 3 weeks since major surgery - Appropriate hematologic, renal and hepatic function in accordance with the following definitions: - Absolute neutrophil count (ANC) = 1.5 × 109 /l - Platelets = 100 × 10 9/l - Total bilirubin = 1.25 times upper limit of normal - Estimated GFR = 50 ml/min - LVEF > 50 % - Informed consent must be obtained from all patients. Exclusion Criteria: - More than one prior chemotherapy (or radiochemotherapy) - Active infection or other serious medical impairment liable to affect the patient's ability to receive treatment according to protocol. - Administration of other chemotherapy drugs or other anticancer hormone treatments during the study. - History of clinically manifest atrial or ventricular arrhythmia (> LOWN II) and congestive heart failure, even if controlled by drugs (NYHA class > II). Documented myocardial infarction within 6 months before study enrollment. - Pregnant or breastfeeding women, or women not practicing appropriate birth control methods - Participation in another study using experimental drugs within the last 30 days - Any other conditions or therapies which the physician believes might put the patient at risk or impair the study objective. - Known hypersensitivity to carboplatin or pegylated liposomal doxorubicin |
Country | Name | City | State |
---|---|---|---|
Germany | Charité, Campus Virchow Klinikum, Frauenklinik | Berlin | |
Germany | Malteser Krankenhaus, Gynäkologie und Geburtshilfe | Bonn | |
Germany | Klinikum Bremen-Mitte gGmbH, Frauenklinik | Bremen | |
Germany | Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe | Dresden | |
Germany | Evangelisches Krankenhaus Düsseldorf, Frauenklinik | Duesseldorf | |
Germany | Universitätsklinikum Essen, Frauenklinik | Essen | |
Germany | Klinikum der J. W. Goethe-Universität, Klinik für Gynäkologie und Geburtshilfe | Frankfurt | |
Germany | University Hospital Hamburg-Eppendorf | Hamburg | |
Germany | Gynäkologisch-onkologische Praxis | Hannover | |
Germany | St. Vincentius Kliniken AG, Frauenklinik | Karlsruhe | |
Germany | Universitätsklinikum Giessen und Marburg GmbH, Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie | Marburg | |
Germany | Klinikum Großhadern, Frauenklinik | München | |
Germany | Universitätsklinikum Tübingen, Frauenklinik | Tübingen | |
Germany | Universitätsklinikum Ulm, Universitätsfrauenklinik | Ulm | |
Germany | Dr. Horst Schmidt Kliniken GmbH, Klinik für Gynäkologie und gynäkologische Onkologie | Wiesbaden |
Lead Sponsor | Collaborator |
---|---|
AGO Study Group | MSD SHARP & DOHME GmbH (formerly Essex Pharma GmbH) |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anticancer activity in terms of progression-free survival time (PFS) | every 3 months | ||
Secondary | Tolerability, i.e. type, frequency, severity and duration of adverse reactions (CTCAE,Version 3.0) | until recovery of toxicities | ||
Secondary | Anticancer activity in patients with measurable or evaluable disease in terms of response rates (CR, PR, SD, PD) according to RECIST criteria | six months | ||
Secondary | Overall survival | 30 months | ||
Secondary | Correlation of tumor marker CA-125 with imaging methods | six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04535271 -
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
|
Phase 2 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT06088290 -
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Terminated |
NCT02940041 -
Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
|
||
Completed |
NCT01442662 -
Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
|
Phase 2 | |
Completed |
NCT00062868 -
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
|
Phase 1 | |
Recruiting |
NCT04214457 -
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
|
||
Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05548179 -
Exploring Clinical Trial Experiences of People With Leiomyosarcoma
|
||
Recruiting |
NCT02983539 -
Detection of Circulating Tumor Cells in Patients With Sarcomas
|
||
Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
Active, not recruiting |
NCT04624178 -
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
|
Phase 2 | |
Terminated |
NCT03959033 -
Patient Reported Outcome Measures (PROMs) With Trabectedin
|
||
Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01956084 -
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
|
Phase 1 | |
Completed |
NCT01426633 -
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
|
Phase 1 | |
Completed |
NCT00400569 -
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT05080790 -
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
|
Phase 2 |